公开(公告)号：US12104181B2

公开(公告)日：2024-10-01

申请号：US17710464

申请日：2022-03-31

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： John W. Schoggins ,  Wenchun Fan ,  Daniel J. Siegwart ,  Qiang Cheng

IPC: A61P31/14 ,  A61K9/51 ,  A61K48/00 ,  C12N9/10

CPC classification number: C12N9/104 ,  A61K9/5123 ,  A61K48/0066 ,  A61P31/14

Abstract: Embodiments of the instant disclosure relate to novel antiviral compositions and methods for treating viral infections. In accordance with these embodiments, antiviral compositions can include at least one mRNA encoding for a TRIM7 protein encapsulated into a lipid nanoparticle (LNP). In other embodiments, methods of making antiviral compositions are disclosed as well as methods of administering a composition having at least one mRNA encoding for a TRIM7 protein encapsulated into LNP into a subject.

公开(公告)号：US20240263151A1

公开(公告)日：2024-08-08

申请号：US17920549

申请日：2021-04-21

Applicant: UNIVERSITY OF DUNDEE

Inventor： Ronald T. HAY ,  Adel F.M. IBRAHIM ,  Linnan SHEN

IPC: C12N9/10 ,  C07K16/00

CPC classification number: C12N9/104 ,  C07K16/00 ,  C07K2317/31 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2319/09

Abstract: The present disclosure provides a novel molecule or construct which can mediate or induce protein degradation. The molecules can be provided in the form of constructs and used to mediate the degradation of specific proteins. The molecules comprise an E3 ligase component and a target protein-binding moiety; this ensures the molecules can be tailored to the degradation of a specific proteinaceaous target.

公开(公告)号：US20230416316A1

公开(公告)日：2023-12-28

申请号：US18247831

申请日：2022-08-29

Applicant: PearlsInMires Co., Ltd.

Inventor： Keun-Yeong JEONG ,  Min Hee PARK

IPC: C07K14/47 ,  C12N9/10 ,  C12N9/12 ,  C12N9/00 ,  C12N9/18 ,  A61P35/00

CPC classification number: C07K14/47 ,  C12N9/104 ,  C12N9/1205 ,  C12N9/1077 ,  A61K38/00 ,  C12N9/18 ,  A61P35/00 ,  C07K2319/10 ,  C12N9/93

Abstract: The present disclosure relates to an adenosine diphosphate (ADP)-ribose binding peptide with anti-cancer activity, and specifically, an ADP-ribose binding peptide having a specific amino acid sequence and a modification thereof, a pharmaceutical composition for preventing or treating cancer comprising the same as an active ingredient, and a pharmaceutical composition for anti-cancer adjuvant. The ADP-ribose binding peptide of the present disclosure has an excellent anti-cancer effect by accumulating ADP-ribose in cancer cells to destroy the balance, thus leading to the death of cancer cells, but not being toxic to normal cells, and when administered in combination with other anti-cancer drugs or anti-cancer radiation therapy, has a very good effect as an anti-cancer adjuvant by enhancing the reactivity to the anti-cancer drugs and radiation therapy.

公开(公告)号：US20180258462A1

公开(公告)日：2018-09-13

申请号：US15922676

申请日：2018-03-15

Applicant: NORTHWESTERN UNIVERSITY

Inventor： Alexander V. Statsyuk ,  Sungjin Park

IPC: C12Q1/25 ,  G01N33/542 ,  C07K14/47

CPC classification number: C12Q1/25 ,  C07K14/47 ,  C07K2319/95 ,  C12N9/104 ,  C12N9/93 ,  C12Y603/02019 ,  G01N33/542 ,  G01N2333/9015 ,  G01N2440/36 ,  G01N2500/00

Abstract: Provided herein is technology relating to the biological process of protein ubiquitination and particularly, but not exclusively, to compositions and methods for studying protein ubiquitination and developing therapeutics to modulate protein ubiquitination.

公开(公告)号：US20180009856A1

公开(公告)日：2018-01-11

申请号：US15593549

申请日：2017-05-12

Applicant: Albumedix A/S

Inventor： Christopher John Arthur Finnis ,  Jennifer Mary Mclaughlan ,  Per Kristoffer Nordeide ,  Preethi Ramaiya

IPC: C07K14/395 ,  C07K1/14 ,  C12N15/04 ,  C12R1/865

CPC classification number: C07K14/395 ,  C07K1/14 ,  C12N1/14 ,  C12N9/104 ,  C12N9/93 ,  C12N15/04 ,  C12N15/63 ,  C12N15/80 ,  C12N15/81 ,  C12P21/02 ,  C12R1/865 ,  C12Y603/02019

Abstract: The invention provides an improved host strain for production of desired protein.

公开(公告)号：US20170182137A1

公开(公告)日：2017-06-29

申请号：US15300208

申请日：2015-03-27

Applicant: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION

Inventor： Mary L. DISIS ,  Denise CECIL ,  Meredith SLOTA

IPC: A61K39/00 ,  C12N9/10 ,  C07K14/71 ,  C07K14/705 ,  C07K14/47

CPC classification number: A61K39/0011 ,  A61K48/00 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/572 ,  C07K14/4702 ,  C07K14/705 ,  C07K14/70567 ,  C07K14/70596 ,  C07K14/71 ,  C12N9/104 ,  C12Y203/02

Abstract: The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids. The compositions may comprise peptides. The methods described herein include administering a composition comprising an epitope of a peptide to a subject in need thereof.

公开(公告)号：US20160319360A9

公开(公告)日：2016-11-03

申请号：US14188364

申请日：2014-02-24

Applicant: The Chinese University of Hong Kong

Inventor： Kwok-wai Lo ,  Ka-fai To ,  Tin-yun Chung ,  Wai-ming Lung

IPC: C12Q1/68 ,  G01N33/559 ,  G01N33/50 ,  C12N9/00

CPC classification number: C12Q1/6886 ,  C07K14/47 ,  C07K2319/00 ,  C07K2319/20 ,  C12N9/104 ,  C12N9/93 ,  C12Q2600/112 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Y603/02019 ,  G01N33/5011 ,  G01N33/559 ,  G01N33/57407 ,  G01N2333/9015 ,  G01N2800/14 ,  G01N2800/60

Abstract: The present invention provides a method for diagnosing nasopharyngeal cancer in a subject by detecting UBR5-ZNF423 fusion polypeptide or polynucleotide, which is in some cases due to a gene fusion of UBR5-ZNF423. A kit useful for such a method is also provided. In addition, the present invention provides a method for treating nasopharyngeal cancer by eliminating UBR5-ZNF423 gene expression or activity.

公开(公告)号：US20160076074A1

公开(公告)日：2016-03-17

申请号：US14856251

申请日：2015-09-16

Applicant: NORTHWESTERN UNIVERSITY

Inventor： Alexander V. Statsyuk ,  Sungjin Park

IPC: C12Q1/25 ,  C07K14/47

CPC classification number: C12Q1/25 ,  C07K14/47 ,  C07K2319/95 ,  C12N9/104 ,  C12N9/93 ,  C12Y603/02019 ,  G01N33/542 ,  G01N2333/9015 ,  G01N2440/36 ,  G01N2500/00

Abstract: Provided herein is technology relating to the biological process of protein ubiquitination and particularly, but not exclusively, to compositions and methods for studying protein ubiquitination and developing therapeutics to modulate protein ubiquitination.

Abstract translation: 本文提供了与蛋白质泛素化的生物学过程相关的技术，特别地但不排他地涉及用于研究蛋白质泛素化和开发治疗剂以调节蛋白质泛素化的组合物和方法。

公开(公告)号：US20150150225A1

公开(公告)日：2015-06-04

申请号：US14619220

申请日：2015-02-11

Applicant: Probiodrug AG

Inventor： Sigrid Graubner ,  Reinhard Sedlmeier ,  Andreas Becker ,  Stephan Schilling ,  Holger Cynis ,  Hans-Ulrich Demuth

IPC: A01K67/027 ,  G01N33/50 ,  C12N15/85 ,  C12N9/10

CPC classification number: A01K67/0278 ,  A01K67/0275 ,  A01K2217/052 ,  A01K2217/15 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/0312 ,  A01K2267/0318 ,  C12N9/104 ,  C12N15/8509 ,  C12Y203/02005 ,  G01N33/5088 ,  G01N2333/9108 ,  G01N2500/10

Abstract: A transgenic non-human animal for overexpressing isoQC, comprising cells containing a DNA transgene encoding human isoQC, characterized in that said human isoQC comprises the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 75% sequence identity to the amino acid sequence of SEQ ID NO: 1 or a fragment or derivative of the amino acid sequence of SEQ ID NO: 1. Additionally disclosed is a method of screening for biologically active agents that inhibit or promote isoQC.

Abstract translation: 一种用于过表达isoQC的转基因非人动物，其包含含有编码人isoQC的DNA转基因的细胞，其特征在于所述人isoQC包含SEQ ID NO：1的氨基酸序列或与SEQ ID NO：1的氨基酸序列具有至少75％ SEQ ID NO：1的氨基酸序列或SEQ ID NO：1的氨基酸序列的片段或衍生物。另外公开了筛选抑制或促进isoQC的生物活性剂的方法。

公开(公告)号：US20150079644A1

公开(公告)日：2015-03-19

申请号：US14547481

申请日：2014-11-19

Applicant: AJINOMOTO CO., INC.

Inventor： Fumi Shozui ,  Yoshinori Tajima ,  Keiichi Yokoyama

IPC: C12P13/02 ,  C08G73/22

CPC classification number: C12P13/02 ,  C08G73/22 ,  C12N9/104 ,  C12P13/005 ,  Y02P20/52

Abstract: The present invention provides a method for conveniently and efficiently producing a 3-acetylamino-4-hydroxybenzoic acid-type compound that is a stable compound by a process using a microorganism. Specifically the present invention provides a microorganism having an ability to produce 3-amino-4-hydroxybenzoic acid, that is modified so as to increase an activity to form 3-amino-4-hydroxybenzoic acid from dihydroxyacetone phosphate and aspartate semialdehyde, wherein the microorganism is modified so as to increase an N-hydroxyarylamine O-acetyltransferase (NhoA) activity, as well as a method for producing the 3-acetylamino-4-hydroxybenzoic acid-type compound using such a microorganism.

Abstract translation: 本发明提供了通过使用微生物的方法方便有效地制备作为稳定化合物的3-乙酰氨基-4-羟基苯甲酸型化合物的方法。 具体地说，本发明提供具有生产3-氨基-4-羟基苯甲酸的能力的微生物，其被修饰以增加从磷酸二羟丙酮和天冬氨酸半醛形成3-氨基-4-羟基苯甲酸的活性，其中微生物 被修饰以增加N-羟基芳基胺O-乙酰基转移酶（NhoA）活性，以及​​使用这种微生物生产3-乙酰氨基-4-羟基苯甲酸型化合物的方法。